LMAT Stock Recent News

LeMaitre is a long-term compounder with mouth-watering economics and shareholder-friendly management. LMAT shares have rallied 45% since August '23, with increased dividends and improving fundamentals. Management has lengthened the reinvestment runway to deploy funds into the business at an advantage to drive further growth in corporate value.

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.

LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Rick Wise - Stifel Suraj Kalia - Oppenheimer Daniel Stauder - Citizens JMP Michael Sarcone - Jefferies Brett Fishbin - KeyBanc Operator Good day ladies and gentlemen.

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.27 per share a year ago.

BURLINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present virtually at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:30 AM ET.

TOL, WILYY and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 7, 2023.

Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

LMAT, SPXC and BBVA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 5, 2023.